A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea

Sun Bean Kim, Yong Chan Kim, Min Hyung Kim, Je Eun Song, Dong Hyun Oh, Jin Young Ahn, Nam Su Ku, Hye Won Kim, Su Jin Jeong, Sang Hoon Han, Young Goo Song, JunYong Choi, June Myung Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The introduction of highly active antiretroviral therapy (HAART) has extended the life expectancy of persons infected with the human immunodeficiency virus type 1 (HIV-1). However, cardiovascular disease (CVD) is currently an increasing concern for HIV-infected persons. Methods: We conducted a cross-sectional case-control study to evaluate and compare the 10-y cardiovascular risk of HIV-infected Koreans who had been receiving HAART for over 6 months and age- and sex-matched uninfected persons who visited a health promotion center, by calculating Framingham risk scores (FRS). Results: The average 10-y risk for cardiovascular events (FRS) was 7.07% (2-45) in the HIV group and 6.87% (1-37) in the control group (p = 0.77), corresponding to the very low risk group. Among HIV patients, the FRS was above 10% (low to moderate cardiovascular risk) in 19.9% of the patients, and above 20% (high risk) in 1.7% of the patients. In the healthy control group, the FRS was above 10% in 16.8% and above 20% in 2.7% (p = 0.57). The FRS was not significantly different for HIV-infected patients treated with protease inhibitor (PI)-based HAART and those treated with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART (7.26 ± 6.3 and 6.81 ± 4.4, respectively, p = 0.69). Conclusions: The predicted cardiovascular risk of HIV-infected Koreans on HAART by FRS equation was low and similar to that of age- and sex-matched healthy control persons. However, the possibility remains that actual cardiovascular events could be underestimated. The next step for predicting the cardiovascular risk is to calculate the Data Collection of Adverse Events of Anti-HIV Drugs (D:A:D) equation risks.

Original languageEnglish
Pages (from-to)855-862
Number of pages8
JournalScandinavian Journal of Infectious Diseases
Volume45
Issue number11
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Korea
Cardiovascular Diseases
HIV
Highly Active Antiretroviral Therapy
Anti-HIV Agents
Control Groups
Reverse Transcriptase Inhibitors
Life Expectancy
Protease Inhibitors
Health Promotion
HIV-1
Case-Control Studies

All Science Journal Classification (ASJC) codes

  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Kim, Sun Bean ; Kim, Yong Chan ; Kim, Min Hyung ; Song, Je Eun ; Oh, Dong Hyun ; Ahn, Jin Young ; Ku, Nam Su ; Kim, Hye Won ; Jeong, Su Jin ; Han, Sang Hoon ; Song, Young Goo ; Choi, JunYong ; Kim, June Myung. / A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea. In: Scandinavian Journal of Infectious Diseases. 2013 ; Vol. 45, No. 11. pp. 855-862.
@article{f89a80beedd549ea9e54aa9ca39ecbf7,
title = "A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea",
abstract = "Background: The introduction of highly active antiretroviral therapy (HAART) has extended the life expectancy of persons infected with the human immunodeficiency virus type 1 (HIV-1). However, cardiovascular disease (CVD) is currently an increasing concern for HIV-infected persons. Methods: We conducted a cross-sectional case-control study to evaluate and compare the 10-y cardiovascular risk of HIV-infected Koreans who had been receiving HAART for over 6 months and age- and sex-matched uninfected persons who visited a health promotion center, by calculating Framingham risk scores (FRS). Results: The average 10-y risk for cardiovascular events (FRS) was 7.07{\%} (2-45) in the HIV group and 6.87{\%} (1-37) in the control group (p = 0.77), corresponding to the very low risk group. Among HIV patients, the FRS was above 10{\%} (low to moderate cardiovascular risk) in 19.9{\%} of the patients, and above 20{\%} (high risk) in 1.7{\%} of the patients. In the healthy control group, the FRS was above 10{\%} in 16.8{\%} and above 20{\%} in 2.7{\%} (p = 0.57). The FRS was not significantly different for HIV-infected patients treated with protease inhibitor (PI)-based HAART and those treated with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART (7.26 ± 6.3 and 6.81 ± 4.4, respectively, p = 0.69). Conclusions: The predicted cardiovascular risk of HIV-infected Koreans on HAART by FRS equation was low and similar to that of age- and sex-matched healthy control persons. However, the possibility remains that actual cardiovascular events could be underestimated. The next step for predicting the cardiovascular risk is to calculate the Data Collection of Adverse Events of Anti-HIV Drugs (D:A:D) equation risks.",
author = "Kim, {Sun Bean} and Kim, {Yong Chan} and Kim, {Min Hyung} and Song, {Je Eun} and Oh, {Dong Hyun} and Ahn, {Jin Young} and Ku, {Nam Su} and Kim, {Hye Won} and Jeong, {Su Jin} and Han, {Sang Hoon} and Song, {Young Goo} and JunYong Choi and Kim, {June Myung}",
year = "2013",
month = "11",
day = "1",
doi = "10.3109/00365548.2013.813064",
language = "English",
volume = "45",
pages = "855--862",
journal = "Infectious Diseases",
issn = "2374-4235",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

Kim, SB, Kim, YC, Kim, MH, Song, JE, Oh, DH, Ahn, JY, Ku, NS, Kim, HW, Jeong, SJ, Han, SH, Song, YG, Choi, J & Kim, JM 2013, 'A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea', Scandinavian Journal of Infectious Diseases, vol. 45, no. 11, pp. 855-862. https://doi.org/10.3109/00365548.2013.813064

A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea. / Kim, Sun Bean; Kim, Yong Chan; Kim, Min Hyung; Song, Je Eun; Oh, Dong Hyun; Ahn, Jin Young; Ku, Nam Su; Kim, Hye Won; Jeong, Su Jin; Han, Sang Hoon; Song, Young Goo; Choi, JunYong; Kim, June Myung.

In: Scandinavian Journal of Infectious Diseases, Vol. 45, No. 11, 01.11.2013, p. 855-862.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea

AU - Kim, Sun Bean

AU - Kim, Yong Chan

AU - Kim, Min Hyung

AU - Song, Je Eun

AU - Oh, Dong Hyun

AU - Ahn, Jin Young

AU - Ku, Nam Su

AU - Kim, Hye Won

AU - Jeong, Su Jin

AU - Han, Sang Hoon

AU - Song, Young Goo

AU - Choi, JunYong

AU - Kim, June Myung

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background: The introduction of highly active antiretroviral therapy (HAART) has extended the life expectancy of persons infected with the human immunodeficiency virus type 1 (HIV-1). However, cardiovascular disease (CVD) is currently an increasing concern for HIV-infected persons. Methods: We conducted a cross-sectional case-control study to evaluate and compare the 10-y cardiovascular risk of HIV-infected Koreans who had been receiving HAART for over 6 months and age- and sex-matched uninfected persons who visited a health promotion center, by calculating Framingham risk scores (FRS). Results: The average 10-y risk for cardiovascular events (FRS) was 7.07% (2-45) in the HIV group and 6.87% (1-37) in the control group (p = 0.77), corresponding to the very low risk group. Among HIV patients, the FRS was above 10% (low to moderate cardiovascular risk) in 19.9% of the patients, and above 20% (high risk) in 1.7% of the patients. In the healthy control group, the FRS was above 10% in 16.8% and above 20% in 2.7% (p = 0.57). The FRS was not significantly different for HIV-infected patients treated with protease inhibitor (PI)-based HAART and those treated with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART (7.26 ± 6.3 and 6.81 ± 4.4, respectively, p = 0.69). Conclusions: The predicted cardiovascular risk of HIV-infected Koreans on HAART by FRS equation was low and similar to that of age- and sex-matched healthy control persons. However, the possibility remains that actual cardiovascular events could be underestimated. The next step for predicting the cardiovascular risk is to calculate the Data Collection of Adverse Events of Anti-HIV Drugs (D:A:D) equation risks.

AB - Background: The introduction of highly active antiretroviral therapy (HAART) has extended the life expectancy of persons infected with the human immunodeficiency virus type 1 (HIV-1). However, cardiovascular disease (CVD) is currently an increasing concern for HIV-infected persons. Methods: We conducted a cross-sectional case-control study to evaluate and compare the 10-y cardiovascular risk of HIV-infected Koreans who had been receiving HAART for over 6 months and age- and sex-matched uninfected persons who visited a health promotion center, by calculating Framingham risk scores (FRS). Results: The average 10-y risk for cardiovascular events (FRS) was 7.07% (2-45) in the HIV group and 6.87% (1-37) in the control group (p = 0.77), corresponding to the very low risk group. Among HIV patients, the FRS was above 10% (low to moderate cardiovascular risk) in 19.9% of the patients, and above 20% (high risk) in 1.7% of the patients. In the healthy control group, the FRS was above 10% in 16.8% and above 20% in 2.7% (p = 0.57). The FRS was not significantly different for HIV-infected patients treated with protease inhibitor (PI)-based HAART and those treated with non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART (7.26 ± 6.3 and 6.81 ± 4.4, respectively, p = 0.69). Conclusions: The predicted cardiovascular risk of HIV-infected Koreans on HAART by FRS equation was low and similar to that of age- and sex-matched healthy control persons. However, the possibility remains that actual cardiovascular events could be underestimated. The next step for predicting the cardiovascular risk is to calculate the Data Collection of Adverse Events of Anti-HIV Drugs (D:A:D) equation risks.

UR - http://www.scopus.com/inward/record.url?scp=84885935299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885935299&partnerID=8YFLogxK

U2 - 10.3109/00365548.2013.813064

DO - 10.3109/00365548.2013.813064

M3 - Article

C2 - 23968223

AN - SCOPUS:84885935299

VL - 45

SP - 855

EP - 862

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 11

ER -